Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2993620rdf:typepubmed:Citationlld:pubmed
pubmed-article:2993620lifeskim:mentionsumls-concept:C0003286lld:lifeskim
pubmed-article:2993620lifeskim:mentionsumls-concept:C0022248lld:lifeskim
pubmed-article:2993620lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:2993620lifeskim:mentionsumls-concept:C1149380lld:lifeskim
pubmed-article:2993620lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:2993620lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:2993620pubmed:issue9lld:pubmed
pubmed-article:2993620pubmed:dateCreated1985-10-17lld:pubmed
pubmed-article:2993620pubmed:abstractTextA series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines were synthesized and tested for their ability to inhibit the binding of [3H]diazepam to rat brain receptors in vitro. Compounds bearing a phenyl, 4-methoxyphenyl, or methyl group at position 3 and a dialkylamino group at position 6 showed the highest affinity in the binding assay and were subsequently evaluated for their anticonflict and anticonvulsant effects. All of these compounds (5a-1 and 5q) were active in the Vogel rat conflict procedure, but none prevented convulsions in mice induced either by metrazol or bicuculline. 3-Phenyl-6-pyrrolidinylpyridazino[4,3-c]isoquinoline (5d) with a Ki = 11.4 nM in the binding assay exhibited the best potency in the anticonflict assay (MED 5 mg/kg ip) and did not produce neuromuscular impairment at the highest dose tested (50 mg/kg ip).lld:pubmed
pubmed-article:2993620pubmed:languageenglld:pubmed
pubmed-article:2993620pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2993620pubmed:citationSubsetIMlld:pubmed
pubmed-article:2993620pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2993620pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2993620pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2993620pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2993620pubmed:statusMEDLINElld:pubmed
pubmed-article:2993620pubmed:monthSeplld:pubmed
pubmed-article:2993620pubmed:issn0022-2623lld:pubmed
pubmed-article:2993620pubmed:authorpubmed-author:TarziaGGlld:pubmed
pubmed-article:2993620pubmed:authorpubmed-author:LuzzaniFFlld:pubmed
pubmed-article:2993620pubmed:authorpubmed-author:TojaEElld:pubmed
pubmed-article:2993620pubmed:authorpubmed-author:BaroneDDlld:pubmed
pubmed-article:2993620pubmed:authorpubmed-author:GallicoLLlld:pubmed
pubmed-article:2993620pubmed:issnTypePrintlld:pubmed
pubmed-article:2993620pubmed:volume28lld:pubmed
pubmed-article:2993620pubmed:ownerNLMlld:pubmed
pubmed-article:2993620pubmed:authorsCompleteYlld:pubmed
pubmed-article:2993620pubmed:pagination1314-9lld:pubmed
pubmed-article:2993620pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:meshHeadingpubmed-meshheading:2993620-...lld:pubmed
pubmed-article:2993620pubmed:year1985lld:pubmed
pubmed-article:2993620pubmed:articleTitleBenzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.lld:pubmed
pubmed-article:2993620pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2993620pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2993620lld:chembl